Treatment of familial pancreatic cancer and its precursors

Current Treatment Options in Gastroenterology

Volumn 8, Issue 5, 2005, Pages 365-375

  Hruban, Ralph H ^a   Canto, Marcia I ^a   Griffin, Constance ^a   Kern, Scott E ^a   Klein, Alison P ^a   Laheru, Dan ^a   Yeo, Charles J ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ALUMINUM HYDROXIDE; ANTACID AGENT; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BRCA1 PROTEIN; CAPECITABINE; COUMARIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOCHROME P450 3A4; ENZYME INHIBITOR; ERLOTINIB; FLUOROURACIL; GEMCITABINE; MAGNESIUM HYDROXIDE; PROTEIN KINASE LKB1; PROTEIN P16; TRIPLE VACCINE;

ABDOMINAL ABSCESS; ANEMIA; ASPIRATION BIOPSY; BILE DUCT OBSTRUCTION; BOLUS INJECTION; BONE MARROW SUPPRESSION; BYPASS SURGERY; CANCER INVASION; CANCER PALLIATIVE THERAPY; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CELIAC PLEXUS; CHEMOTHERAPY INDUCED EMESIS; CHOLANGITIS; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIARRHEA; DIETARY INTAKE; DNA DETERMINATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG EXCRETION; DRUG METABOLISM; DYSPNEA; EARLY DIAGNOSIS; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENUCLEATION; FAMILIAL CANCER; FATIGUE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HEART ARRHYTHMIA; HEMOLYTIC UREMIC SYNDROME; HIGH RISK POPULATION; HUMAN; INCISIONAL HERNIA; LIFESTYLE; LIVER METABOLISM; LIVER TOXICITY; LONG TERM CARE; METASTASIS POTENTIAL; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIMODALITY CANCER THERAPY; NERVE BLOCK; NEUROLYSIS; NEUROTOXICITY; NEUTROPENIA; PANCREAS CANCER; PANCREAS FISTULA; PANCREAS HEMORRHAGE; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PANCREATOGRAPHY; PATIENT COUNSELING; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRECANCER; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RNA ANALYSIS; SMOKING CESSATION; STENT; STOMACH EMPTYING; STOMATITIS; SURGICAL RISK; SURGICAL TECHNIQUE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; TUMOR SUPPRESSOR GENE; URINARY EXCRETION; WEIGHT REDUCTION; WOUND INFECTION;

EID: 28044444895     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-005-0039-3     Document Type: Review

References (35)

1. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8-29.
2. Surveillance, Epidemiology, and End Results (SEER) Program (http://www.seer.cancer.gov) SEER*Stat Data-bases: Incidence - SEER 11 Regs + AK Public-Use, Nov 2003 Sub for Expanded Races (1992-2001) and Incidence - SEER 11 Regs Public-Use, Nov 2003 Sub for Hispanics (1992-2001), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2004, based on the November 2003 submission. 2004.
3. Klein AP, Brune K, Petersen GM, et al.: Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004, 64:2634-2638.
4. Murphy KM, Brune KA, Griffin CA, et al.: Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in Familial Pancreatic Cancer: Deleterious BRCA2 Mutations in 17%. Cancer Res 2002, 62:3789-3793.
5. Ozcelik H, Schmocker B, DiNicola N, et al.: Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet 1997, 16:17-18.
6. Lynch HT, Brand RE, Lynch JF, et al.: Genetic counseling and testing for germline p16 mutations in two pancreatic cancer-prone families. Gastroenterology 2000, 119:1756-1760.
7. Giardiello FM, Welsh SB, Hamilton SR, et al.: Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med 1987, 316:1511-1514.
8. Lowenfels AB, Maisonneuve EP, Dimagno YE, et al.: Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997, 89:442-446.
9. Lynch HT, Voorhees GJ, Lanspa SJ, et al.: Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. Br J Cancer 1985, 52:271-273.
10. Amundadottir LT, Thorvaldsson S, Gudbjartsson DF, et al.: Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. PLoS Med 2004, 1:e65.
11. Klein AP, BeatyTH, Bailey-Wilson JE, et al.: Evidence for a major gene influencing risk of pancreatic cancer. Genet Epidemiol 2002, 23:133-149.
12. Michaud DS, Giovannucci E, Willett WC, et al.: Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 2001, 286:921-929.
13. Cuzick I, Babiker AG: Pancreatic cancer, alcohol, diabetes mellitus and gallbladder disease. Int J Cancer 1989, 43:415-421.
14. Canto MI, Goggins M, Yeo CJ, et al.: Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. In press.
15. Sohn TA, Yeo CJ, Lillemoe KD, et al.: Resected adenocarcinoma of the pancreas - 616 patients: Results, outcome, and prognostic indications. J Gastroenterol Surg 2000, 4:567-579.
16. Kalser MH, Ellenberg SS: Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985, 120:899-903.
17. Klinkenbijl JH, Jeekel J, Sahmoud T, et al.: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999, 230:776-782.
18. Chakravarthy A, Abrams RA, Yeo CJ, et al.: Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. Int J Radiat Oncol Biol Phys 2000, 48:1089-1096.
19. Allen AM, Zalupski MM, Robertson JM, et al.: Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine. Int J Radiat Oncol Biol Phys 2004, 59:1461-1467.
20. Neoptolemos JP, Stocken DD, Friess H, et al.: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004, 350:1200-1210.
21. Jaffee EM, Hruban RH, Biedrzycki B, et al.: Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001, 19:145-156.
22. Picozzi VJ, Kozarek RA, Traverso LW: Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2003, 185:476-480.
23. Burris HA, III, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-2413.
24. Heinemann V, Quietzsch D, Gieseter M, et al.: A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma [abstract]. Proc ASCO 2003, 22:250.
25. Rocha Lima CMS, Rotche R, Jeffery M, et al.: A randomized phase 3 study comparing efficacy and safety of gemcitabine (GEM) and irinotecan (I), to GEM alone in patients (pst) with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy [abstract]. Proc ASCO 2003, 22:251.
26. Tempero M, Plunkett W, Ruiz VH, et al.: Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003, 21:3402-3408.
27. Louvet C, Labianca R, Hammel P, et al.: GemOx (Gemcitabine + Oxaliplatin) versus Gem (Gemcitabine) in non resectable pancreatic adenocarcinoma: final results of the GERCOR/GISCAD Intergroup Phase III [abstract 4008]. Proc ASCO 2004, 22:314.
28. Cheverton P, Friess H, Andras C, et al.: Phase III results of exatecan (CX-8951f) versus gemcitabine (Gem) in chemotherapy-naive patients with advanced pancreatic cancer (APC) [abstract 4005]. Proc ASCO 2004, 23:314.
29. Richards DA, Kindler HL, Oettle H, et al.: A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer [abstract 4007]. Proc ASCO 2004, 23:314.
30. Xiong HQ, Rosenberg A, LoBuglio A, et al.: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 2004, 22:2610-2616.
31. Moore MJ, Goldstein D, Hamm J, et al.: Erlotinib plus gemcitabine compared to gemcitabine along in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) [abstract 1]. Proc GI Am Soc Clin Oncol 2005, 24:1.
32. Rulyak SJ, Kimmey MB, Veenstra DL, Brentnall TA: Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc 2003, 57:23-29.
33. Yeo CJ, Yeo TP, Hruban RH, et al.: Cancer of the pancreas. In Cancer: Principles and Practice in Oncology, edn 7. Edited by DeVita, Hellman S, Rosenberg SA. Philadelphia: Lippincott Williams and Wilkins; 2005:945-986.
34. Yeo CJ, Cameron JL, Lillemoe KD, et al.: Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 2002, 236:355-366.
35. Shi C, Eshleman SH, Jones D, et al.: LigAmp for sensitive detection of single-nucleotide differences. Nat Methods 2004, 1:141-147.